Radical cystectomy over the age of 75 is safe and increases survival

Autor: Tyritzis, Stavros I. Anastasiou, Ioannis Stravodimos, Konstantinos G. Alevizopoulos, Aristeides Kollias, Anastasios and Balangas, Antonios Katafigiotis, Ioannis Leotsakos, Ioannis and Mitropoulos, Dionysios Constantinides, Constantinos A.
Jazyk: angličtina
Rok vydání: 2012
Popis: Background: Radical cystectomy (RC) is probably underused in elderly patients due to a potential increased postoperative complication risk, as reflected by their considerable comorbidities. Our objective was to estimate the overall complication rate and investigate a potential benefit to patients over the age of 75 subjected to RC in terms of disease-free survival. Methods: A total of 81 patients, 61 men and 20 women, from two urological departments, with a mean age of 79.2 +/- 3.7 years, participated in the study. The mean follow-up period was 2.6 +/- 1.6 years. All patients underwent RC with pelvic lymphadenectomy. An ileal conduit, an orthotopic ileal neobladder and cutaneous ureterostomies were formed in 48.1%, 6.2% and 45.7% of the patients, respectively. The perioperative and 90-day postoperative complications were recorded and classified according to the modified Clavien classification system. Survival plots were created based on the oncological outcome and several study parameters. Results: The perioperative morbidity rate was 43.2%; the 90-day morbidity rate was 37%, while the 30-day, 90-day and overall mortality rates were 3.7%, 3.7% and 21%, respectively. Overall mortality rates were recorded at the final year of data gathering (2009). Increased age, increased body mass index (BMI), longer hospitalization and age-adjusted Charlson comorbidity index (ACCI) more than six, were associated with greater hazard for 90-day morbidity. The cumulative mortality /metastasis-free rates for one, two, three and five years were 88.7%, 77.5%, 70.4%, and 62.3%, respectively. Tumour stage and positive nodes were prognostic predictors for oncological outcome. Conclusions: RC in patients over 75 is justified and feasible, due to acceptable complication rates and high 5-year cancer-specific survival, which support an aggressive approach. Prospective studies are needed for the verification of the above results.
Databáze: OpenAIRE